CClinicalTrials.gg
Sign In
CompletedNCT03748953Updated Mar 21, 2025Results posted

Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Participants With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation (SCT)

A Phase 3 interventional study of Ixazomib in Multiple Myeloma, sponsored by Millennium Pharmaceuticals, Inc.. Completed at 10 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-21.

Sponsored by Millennium Pharmaceuticals, Inc. · Phase 3, Interventional, and Treatment

Phase
Phase 3
Study type
Interventional
Enrollment
37
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to determine the long-term safety and tolerability of ixazomib maintenance therapy.

Read the detailed description

The drug being tested in this study is called ixazomib. Ixazomib is being tested to slow disease progression and improve overall survival in Chinese participants who have newly diagnosed multiple myeloma (NDMM) who have had a major positive response to initial therapy and have not undergone stem cell transplantation (SCT). This study will look at the effect of ixazomib has on the length of time that participants are free of disease progression and their overall survival. After the implementation of Amendment 8, participants who received placebo-matching capsules before unblinding and have not yet experienced disease progression will cross over to receive ixazomib.

The study will enroll approximately 37 patients. Participants will be assigned to a single treatment group

  • Ixazomib

All participants will be asked to take one capsule on Days 1, 8, and 15 of every 28-day cycle, for up to approximately 24 months (equivalent to 26 cycles [if no cycle delays], to the nearest complete cycle) or until documented progressive disease (PD) or intolerable toxicity, whichever occurs first.

This multi-center trial will be conducted in China. The overall time to participate in this study is until a total of approximately up to 60 months. Participants will make multiple visits to the clinic, and every 4 weeks until the next line of therapy begins for a follow-up assessment.

02

Conditions studied

  • Multiple Myeloma

Keywords

  • Drug Therapy
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Adult male or female participants aged 18 years or older with a confirmed diagnosis of symptomatic NDMM according to standard criteria.
  2. Has completed 6 to 12 months (±2 weeks) of initial therapy, during which the participant was treated to best response, defined as the best response maintained for 2 cycles after the M-protein nadir is reached.
  3. Has documented major response (partial response [PR], very good partial response [VGPR], complete response [CR]) according to the international myeloma working group (IMWG) uniform response criteria, version 2011, after this initial therapy.

  4. Female participants who:

    Are postmenopausal for at least 1 year before the screening visit, OR Are surgically sterile, OR If they are of childbearing potential, agree to practice 2 effective methods of contraception, at the same time, from the time of signing the informed consent through 90 days after the last dose of study drug, or Agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the participant. (Periodic abstinence [e.g., calendar, ovulation,symptothermal, postovulation methods] and withdrawal are not acceptable methods of contraception.)

    Male participants, even if surgically sterilized (i.e., status postvasectomy), who:

    Agree to practice effective barrier contraception during the entire study Treatment period and through 90 days after the last dose of study drug, or Agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the participant. (Periodic abstinence [e.g., calendar, ovulation, symptothermal, postovulation methods for the female partner] and withdrawal are not acceptable methods of contraception.)

  5. Voluntary written consent must be given before performance of any study-related procedure not part of standard medical care, with the understanding that consent may be withdrawn by the participant at any time without prejudice to future medical care.

  6. Has availability of complete documentation for:

    1. Details of initial disease state, initial therapy, and response
    2. Cytogenetic assessment at diagnosis (cytogenetic assessment performed after diagnosis must be approved by a Takeda project clinician or designee)
    3. International Staging System (ISS) staging at diagnosis (requiring beta 2-microglobulin and serum albumin results).
  7. Has Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2.
  8. Suitable venous access for the study-required blood sampling and consent for the specific amounts that will be taken.
  9. Participant is willing and able to adhere to the study visit schedule and other protocol requirements including blood sampling and bone marrow aspiration.
  10. Participants must meet the following clinical laboratory criteria at study entry:
  1. Absolute neutrophil count (ANC) ≥1,000/mm\^3 without growth factor support and platelet count ≥ 75,000/mm\^3. Platelet transfusions to help participants meet eligibility criteria are not allowed within 3 days before enrollment.
  1. Total bilirubin ≤1.5*the upper limit of the normal range (ULN). 3. Alanine aminotransferase and aspartate aminotransferase ≤3*ULN. 4. Calculated creatinine clearance ≥30 mL/min (using the Cockroft-Gault equation).

Exclusion criteria

Exclusion Criteria:

  1. Has multiple myeloma that relapsed after, or was not responsive to, initial therapy.
  2. Had prior stem-cell transplantation (SCT).
  3. Has radiotherapy within 14 days before enrollment.
  4. Had been diagnosed or treated for another malignancy within 5 years before enrollment or previously diagnosed with another malignancy with evidence of residual disease. Participants with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection.
  5. Female participants who are lactating and breastfeeding or have a positive serum pregnancy test during the Screening period.
  6. Has major surgery within 14 days before enrollment.
  7. Has central nervous system involvement.
  8. Infection requiring intravenous (IV) antibiotic therapy or other serious infection within 14 days before enrollment.
  9. Has diagnosis of Waldenstrom's macroglobulinemia, polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) syndrome, plasma cell leukemia, primary amyloidosis, myelodysplastic syndrome, or myeloproliferative syndrome.
  10. Evidence of current uncontrolled cardiovascular conditions, including uncontrolled hypertension, uncontrolled cardiac arrhythmias, uncontrolled congestive heart failure, unstable angina, or myocardial infarction within the past 6 months.
  11. Systemic treatment with strong cytochrome P450 (CYP3A) inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital) or use of St. John's wort within 14 days before enrollment.
  12. Ongoing or active infection, known human immunodeficiency virus positive, active hepatitis B or C infection.
  13. Has comorbid systemic illnesses or other severe concurrent disease that, in the judgment of the investigator, would make the participant inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens (e.g., peripheral neuropathy (PN) that is Grade 1 with pain or Grade 2 or higher of any cause).
  14. Psychiatric illness/social situation that would limit compliance with study requirements.
  15. Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent.
  16. Inability to swallow oral medication, inability or unwillingness to comply with the drug administration requirements, or gastrointestinal (GI) procedure that could interfere with the oral absorption or tolerance of treatment.
  17. Treatment with any investigational products within 30 days before enrollment.
04

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
37 participants (actual)

Study arms

  • Experimental
    Ixazomib

    Participants received ixazomib 3 milligrams (mg), capsules, orally, once on Days 1, 8, and 15 for Cycles 1 through 4, during which if the participants tolerated the initial dose, the dose was escalated to ixazomib 4 mg, capsules, orally, once on Days 1, 8, and 15 for Cycles 5 through 26, or until documented PD or intolerable toxicity, whichever occurred first (cycle length=28 days).

    Drug: Ixazomib

Interventions

  • DrugIxazomib

    Ixazomib Capsules

05

What researchers measure

Primary outcomes

  1. Number of Participants Categorized According to Performance Status (PS) Based on Eastern Cooperative Oncology Group (ECOG) PS

    ECOG PS was used to assess physical health of participants. ECOG PS grade:0= fully active, able to carry on all pre-disease performance without restriction,1= restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature 2= ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 50% of waking hours, 3= capable of only limited self-care, 4= completely disabled, cannot carry on any selfcare, totally confined to bed or chair confined to bed or chair more than 50% of waking hours and 5= dead. Only those categories with non-zero values were reported.

    Time frame: Month 25

  2. Percentage of Participants Receiving Ixazomib With Treatment-emergent Adverse Events (TEAEs)

    Adverse events (AEs) were defined as any unfavorable and unintended sign, symptom or disease temporally associated with the use of a medicinal product reported from first dose of study drug through 30 days after the last dose of study drug. A TEAE was defined as an AE that started or worsened after first study drug administration and within 30 days of last dose of study drug. Percentages are rounded off to the nearest whole number.

    Time frame: Up to 58.4 months

  3. Percentage of Participants Receiving Ixazomib With Treatment-emergent Serious Adverse Events (SAEs)

    AEs were defined as any unfavorable and unintended sign, symptom or disease temporally associated with the use of a medicinal product reported from first dose of study drug through 30 days after the last dose of study drug. A TEAE was defined as an AE that started or worsened after first study drug administration and within 30 days of last dose of study drug. An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability or incapacity, was a congenital abnormality or birth defect, or is an important medical event. Percentages are rounded off to the nearest whole number.

    Time frame: Up to 58.4 months

  4. Number of Participants Receiving Ixazomib With Clinically Significant Changes in Safety Laboratory Values

    Clinical laboratory assessments included hematology, serum chemistry, and urinalysis. Any clinically significant changes in the clinical laboratory value over time based on the investigator's interpretation were reported.

    Time frame: Up to 58.4 months

Secondary outcomes

  1. Progression-Free Survival (PFS)

    PFS was defined as the time from the date of first dose of study drug to the first occurrence of PD as evaluated by the investigator or death from any cause, whichever occurred first. PD was defined as ≥25% increase from lowest value in serum M component or urine M-component; difference between involved and uninvolved free light chain (FLC) levels (absolute increase \>10 milligrams per deciliter \[mg/dL\]); bone marrow plasma cell percent ≥10%; new bone lesions or soft tissue plasmacytomas development or definite increase in existing bone lesions/soft tissue plasmacytomas size; hypercalcaemia development.

    Time frame: From the first dose of study drug to every 4 weeks until PD or death from any cause (up to 58.4 months)

  2. Overall Survival (OS)

    OS was measured as the time from the date of first dose of study drug to the date of death.

    Time frame: From the first dose of study drug to every 12 weeks during follow-up after PD or next line therapy or death whichever occurred later (up to 58.4 months)

  3. Percentage of Participants Who Achieved or Maintained Best Response Before PD or up to Subsequent Therapy

    Response was assessed according to International Myeloma Working Group (IMWG) criteria. Best response includes partial response (PR), very good partial response (VGPR), and complete response (CR). PR as per IMWG criteria is 50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by ≥90% or to less than (\<)200 mg per 24 hours. VGPR is serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum M-protein plus urine M-protein level \<100 mg per 24 hours. CR is negative immunofixation of serum and urine and disappearance of soft tissue plasmacytomas and \<5% plasma cells in bone marrow. Percentages are rounded off to the nearest whole number.

    Time frame: Up to 58.4 months

  4. Duration of Complete Response (CR)

    Duration of CR was defined as the time from the date of first dose of study drug or the date of CR to the date of first documentation of PD. CR was defined as negative immunofixation on the serum and urine; soft tissue plasmacytomas disappearance; \<5% plasma cells (PCs) in bone marrow.

    Time frame: Up to 58.4 months

  5. Time to Progression (TTP)

    TTP was defined as the time from the date of first dose of study drug to the date of first documentation of PD. PD was defined as ≥25% increase from lowest value in serum M component or urine M-component; difference between involved and uninvolved FLC levels (absolute increase \>10 mg/dL); bone marrow plasma cell percent ≥10%; new bone lesions or soft tissue plasmacytomas development or definite increase in existing bone lesions/soft tissue plasmacytomas size; hypercalcaemia development.

    Time frame: Up to 58.4 months

  6. Time to Next-Line Therapy (TTNT)

    TTNT was defined as the time from the date of first dose of study drug to the date of the first dose of next-line of antineoplastic therapy.

    Time frame: Up to 58.4 months

  7. Percentage of Participants With A New Primary Malignancy

    Time frame: Up to 58.4 months

  8. Change From Baseline in the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-C30 as Measured by the Global Health Status (GHS)

    The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. The change from baseline in GHS (EORTC QLQ-C30) score is presented. Participant responses to the question "How would you rate your overall health during the past week?" are scored on a 7-point scale (1=very poor to 7=excellent). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher score indicates a better overall GHS.

    Time frame: Baseline, Cycle 26 (cycle length=28 days)

  9. Correlation Between Frailty Status and PFS

    Participant's frailty status is classified as fit, unfit, or frail on the basis of 4 components: age, the Charlson comorbidity scoring system without age weighting, the Katz index of independence in activities of daily living, and the Lawton instrumental activities of daily living scale. The sum of the 4 frailty scores equals the total frailty score. A total frailty score of 0 corresponds to a frailty status of fit; a total score of 1, to unfit; and a total score of 2 or more, to frail. PFS is defined as the time from the date of first dose of study drug to the first occurrence of PD as evaluated by the investigator.

    Time frame: Up to 58.4 months

  10. Correlation Between Frailty Status and OS

    Participant's frailty status is classified as fit, unfit, or frail on the basis of 4 components: age, the Charlson comorbidity scoring system without age weighting, the Katz index of independence in activities of daily living, and the Lawton instrumental activities of daily living scale. The sum of the 4 frailty scores equals the total frailty score. A total frailty score of 0 corresponds to a frailty status of fit; a total score of 1, to unfit; and a total score of 2 or more, to frail. OS was measured as the time from the date of first dose of study drug to the date of death.

    Time frame: Up to 58.4 months

  11. Plasma Concentration of Ixazomib

    Plasma concentrations of the complete hydrolysis product of ixazomib citrate (ixazomib) were measured using a validated liquid chromatography-tandem mass spectrometry (LC/MS/MS) assay.

    Time frame: Cycle 1 (1 and 4 hours post-dose Day 1, Days 8 and 15 pre-dose); Cycle 2 and 5 (Days 1 and 8 pre-dose) and Cycles 3, 4, 6 to 10 (Day 1 pre-dose) (cycle length=28 days)

  12. Time to Resolution of Peripheral Neuropathy (PN) Events

    PN is defined as the event in the high-level term of peripheral neuropathies not elsewhere classified (NEC) according to the medical dictionary for regulatory activities (MedDRA). A PN event was considered as resolved if its final outcome was resolved with no subsequent PN event of the same preferred term occurring on the resolution date or the day before and after. Time to resolution was defined as the time from the initial onset date (inclusive) to the resolution date for resolved events.

    Time frame: Up to 58.4 months

  13. Time to Improvement of PN Events

    PN is defined as the event in the high-level term of peripheral neuropathies NEC according to the MedDRA. A PN event is considered to be improved if the event improves from the maximum grade; that is, all the grades recorded after the maximum grade are less than the maximum grade. Time to improvement is defined as the time from the initial onset date (inclusive) of the maximum grade to the first onset date that the toxicity grade is below the maximum grade with no higher grade thereafter, or the resolution date, whichever occurs first.

    Time frame: Up to 58.4 months

06

Results

Posted Mar 21, 2025

Participant flow

A total of 37 participants (31 enrolled in this study and 6 rolled over from study C16021\[NCT02312258\]) with a diagnosis of newly diagnosed multiple myeloma (NDMM) not treated with stem cell transplantation (SCT) took part in the study at investigative sites in China from 24 January 2019 to 06 December 2023.

Treatment Prior to Amendment 08
Participant flow — Treatment Prior to Amendment 08
MilestoneIxazomibPlacebo
Started64
Placebo safety population04
Completed60
Not completed04
Withdrew: Discontinued to switch to ixazomib02
Withdrew: Reason not specified02
Treatment Post Amendment 08
Participant flow — Treatment Post Amendment 08
MilestoneIxazomibPlacebo
Started350
Efficacy population330
Ixazomib safety population350
Completed00
Not completed350
Withdrew: Withdrawal by subject180
Withdrew: Reason not specified160
Withdrew: Lost to follow-up10

Outcome measures

PrimaryNumber of Participants Categorized According to Performance Status (PS) Based on Eastern Cooperative Oncology Group (ECOG) PS

ECOG PS was used to assess physical health of participants. ECOG PS grade:0= fully active, able to carry on all pre-disease performance without restriction,1= restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature 2= ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 50% of waking hours, 3= capable of only limited self-care, 4= completely disabled, cannot carry on any selfcare, totally confined to bed or chair confined to bed or chair more than 50% of waking hours and 5= dead. Only those categories with non-zero values were reported.

Time frame:
Month 25
Reported as:
Count of participants · Participants
Number of Participants Categorized According to Performance Status (PS) Based on Eastern Cooperative Oncology Group (ECOG) PS
ParticipantsIxazomib
ECOG Score 034
ECOG Score 11
PrimaryPercentage of Participants Receiving Ixazomib With Treatment-emergent Adverse Events (TEAEs)

Adverse events (AEs) were defined as any unfavorable and unintended sign, symptom or disease temporally associated with the use of a medicinal product reported from first dose of study drug through 30 days after the last dose of study drug. A TEAE was defined as an AE that started or worsened after first study drug administration and within 30 days of last dose of study drug. Percentages are rounded off to the nearest whole number.

Time frame:
Up to 58.4 months
Reported as:
Number · percentage of participants
Percentage of Participants Receiving Ixazomib With Treatment-emergent Adverse Events (TEAEs)
percentage of participantsIxazomib
Percentage of Participants Receiving Ixazomib With Treatment-emergent Adverse Events (TEAEs)97
PrimaryPercentage of Participants Receiving Ixazomib With Treatment-emergent Serious Adverse Events (SAEs)

AEs were defined as any unfavorable and unintended sign, symptom or disease temporally associated with the use of a medicinal product reported from first dose of study drug through 30 days after the last dose of study drug. A TEAE was defined as an AE that started or worsened after first study drug administration and within 30 days of last dose of study drug. An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability or incapacity, was a congenital abnormality or birth defect, or is an important medical event. Percentages are rounded off to the nearest whole number.

Time frame:
Up to 58.4 months
Reported as:
Number · percentage of participants
Percentage of Participants Receiving Ixazomib With Treatment-emergent Serious Adverse Events (SAEs)
percentage of participantsIxazomib
Percentage of Participants Receiving Ixazomib With Treatment-emergent Serious Adverse Events (SAEs)31
PrimaryNumber of Participants Receiving Ixazomib With Clinically Significant Changes in Safety Laboratory Values

Clinical laboratory assessments included hematology, serum chemistry, and urinalysis. Any clinically significant changes in the clinical laboratory value over time based on the investigator's interpretation were reported.

Time frame:
Up to 58.4 months
Reported as:
Count of participants · Participants
Number of Participants Receiving Ixazomib With Clinically Significant Changes in Safety Laboratory Values
ParticipantsIxazomib
Number of Participants Receiving Ixazomib With Clinically Significant Changes in Safety Laboratory Values0
SecondaryProgression-Free Survival (PFS)

PFS was defined as the time from the date of first dose of study drug to the first occurrence of PD as evaluated by the investigator or death from any cause, whichever occurred first. PD was defined as ≥25% increase from lowest value in serum M component or urine M-component; difference between involved and uninvolved free light chain (FLC) levels (absolute increase \>10 milligrams per deciliter \[mg/dL\]); bone marrow plasma cell percent ≥10%; new bone lesions or soft tissue plasmacytomas development or definite increase in existing bone lesions/soft tissue plasmacytomas size; hypercalcaemia development.

Time frame:
From the first dose of study drug to every 4 weeks until PD or death from any cause (up to 58.4 months)
Reported as:
Median · months
Progression-Free Survival (PFS)
monthsIxazomib
Progression-Free Survival (PFS)21.3 (9.20 to NA)
SecondaryOverall Survival (OS)

OS was measured as the time from the date of first dose of study drug to the date of death.

Time frame:
From the first dose of study drug to every 12 weeks during follow-up after PD or next line therapy or death whichever occurred later (up to 58.4 months)
Reported as:
Median · months
Overall Survival (OS)
monthsIxazomib
Overall Survival (OS)NA (NA to NA)
SecondaryPercentage of Participants Who Achieved or Maintained Best Response Before PD or up to Subsequent Therapy

Response was assessed according to International Myeloma Working Group (IMWG) criteria. Best response includes partial response (PR), very good partial response (VGPR), and complete response (CR). PR as per IMWG criteria is 50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by ≥90% or to less than (\<)200 mg per 24 hours. VGPR is serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum M-protein plus urine M-protein level \<100 mg per 24 hours. CR is negative immunofixation of serum and urine and disappearance of soft tissue plasmacytomas and \<5% plasma cells in bone marrow. Percentages are rounded off to the nearest whole number.

Time frame:
Up to 58.4 months
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved or Maintained Best Response Before PD or up to Subsequent Therapy
percentage of participantsIxazomib
PR3
VGPR12
CR76
SecondaryDuration of Complete Response (CR)

Duration of CR was defined as the time from the date of first dose of study drug or the date of CR to the date of first documentation of PD. CR was defined as negative immunofixation on the serum and urine; soft tissue plasmacytomas disappearance; \<5% plasma cells (PCs) in bone marrow.

Time frame:
Up to 58.4 months
Reported as:
Median · months
Duration of Complete Response (CR)
monthsIxazomib
Duration of Complete Response (CR)NA (12.88 to NA)
SecondaryTime to Progression (TTP)

TTP was defined as the time from the date of first dose of study drug to the date of first documentation of PD. PD was defined as ≥25% increase from lowest value in serum M component or urine M-component; difference between involved and uninvolved FLC levels (absolute increase \>10 mg/dL); bone marrow plasma cell percent ≥10%; new bone lesions or soft tissue plasmacytomas development or definite increase in existing bone lesions/soft tissue plasmacytomas size; hypercalcaemia development.

Time frame:
Up to 58.4 months
Reported as:
Median · months
Time to Progression (TTP)
monthsIxazomib
Time to Progression (TTP)21.3 (9.20 to NA)
SecondaryTime to Next-Line Therapy (TTNT)

TTNT was defined as the time from the date of first dose of study drug to the date of the first dose of next-line of antineoplastic therapy.

Time frame:
Up to 58.4 months
Reported as:
Median · months
Time to Next-Line Therapy (TTNT)
monthsIxazomib
Time to Next-Line Therapy (TTNT)NA (24.48 to NA)
SecondaryPercentage of Participants With A New Primary Malignancy
Time frame:
Up to 58.4 months
Reported as:
Number · percentage of participants
Percentage of Participants With A New Primary Malignancy
percentage of participantsIxazomib
Percentage of Participants With A New Primary Malignancy0
SecondaryChange From Baseline in the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-C30 as Measured by the Global Health Status (GHS)

The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. The change from baseline in GHS (EORTC QLQ-C30) score is presented. Participant responses to the question "How would you rate your overall health during the past week?" are scored on a 7-point scale (1=very poor to 7=excellent). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher score indicates a better overall GHS.

Time frame:
Baseline, Cycle 26 (cycle length=28 days)
Reported as:
Mean · score on a scale
Change From Baseline in the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-C30 as Measured by the Global Health Status (GHS)
score on a scaleIxazomib
Change From Baseline in the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-C30 as Measured by the Global Health Status (GHS)-5.3 ± 15.49
SecondaryCorrelation Between Frailty Status and PFS

Participant's frailty status is classified as fit, unfit, or frail on the basis of 4 components: age, the Charlson comorbidity scoring system without age weighting, the Katz index of independence in activities of daily living, and the Lawton instrumental activities of daily living scale. The sum of the 4 frailty scores equals the total frailty score. A total frailty score of 0 corresponds to a frailty status of fit; a total score of 1, to unfit; and a total score of 2 or more, to frail. PFS is defined as the time from the date of first dose of study drug to the first occurrence of PD as evaluated by the investigator.

Time frame:
Up to 58.4 months
Reported as:
Median · months
Correlation Between Frailty Status and PFS
monthsIxazomib
Frailty Status: FitNA (12.68 to NA)
Frailty Status: Unfit20.9 (0.89 to NA)
Frailty Status: Frail6.5 (6.18 to NA)
SecondaryCorrelation Between Frailty Status and OS

Participant's frailty status is classified as fit, unfit, or frail on the basis of 4 components: age, the Charlson comorbidity scoring system without age weighting, the Katz index of independence in activities of daily living, and the Lawton instrumental activities of daily living scale. The sum of the 4 frailty scores equals the total frailty score. A total frailty score of 0 corresponds to a frailty status of fit; a total score of 1, to unfit; and a total score of 2 or more, to frail. OS was measured as the time from the date of first dose of study drug to the date of death.

Time frame:
Up to 58.4 months
Reported as:
Median · months
Correlation Between Frailty Status and OS
monthsIxazomib
Frailty Status: FitNA (NA to NA)
Frailty Status: UnfitNA (NA to NA)
Frailty Status: FrailNA (NA to NA)
SecondaryPlasma Concentration of Ixazomib

Plasma concentrations of the complete hydrolysis product of ixazomib citrate (ixazomib) were measured using a validated liquid chromatography-tandem mass spectrometry (LC/MS/MS) assay.

Time frame:
Cycle 1 (1 and 4 hours post-dose Day 1, Days 8 and 15 pre-dose); Cycle 2 and 5 (Days 1 and 8 pre-dose) and Cycles 3, 4, 6 to 10 (Day 1 pre-dose) (cycle length=28 days)
Reported as:
Geometric mean · nanograms per milliliter (ng/mL)
Plasma Concentration of Ixazomib
nanograms per milliliter (ng/mL)Ixazomib
Cycle 1 Day 1: 1 Hour Post-dose15.3 ± 181
Cycle 1 Day 1: 4 Hours Post-dose16.6 ± 94.4
Cycle 1 Day 8: Pre-dose2.25 ± 51.5
Cycle 1 Day 15: Pre-dose4 ± 53.6
Cycle 2 Day 1: Pre-dose2.92 ± 46.8
Cycle 2 Day 8: Pre-dose4.37 ± 42.5
Cycle 3 Day 1: Pre-dose3.15 ± 41.9
Cycle 4 Day 1: Pre-dose3.16 ± 59.4
Cycle 5 Day 1: Pre-dose3.25 ± 42.1
Cycle 5 Day 8: Pre-dose5.29 ± 36.9
Cycle 6 Day 1: Pre-dose3.58 ± 41.3
Cycle 7 Day 1: Pre-dose4.04 ± 48.5
Cycle 8 Day 1: Pre-dose3.28 ± 64.7
Cycle 9 Day 1: Pre-dose3.7 ± 31.3
Cycle 10 Day 1: Pre-dose2.99 ± 37.6
SecondaryTime to Resolution of Peripheral Neuropathy (PN) Events

PN is defined as the event in the high-level term of peripheral neuropathies not elsewhere classified (NEC) according to the medical dictionary for regulatory activities (MedDRA). A PN event was considered as resolved if its final outcome was resolved with no subsequent PN event of the same preferred term occurring on the resolution date or the day before and after. Time to resolution was defined as the time from the initial onset date (inclusive) to the resolution date for resolved events.

Time frame:
Up to 58.4 months
Reported as:
Median · days
Time to Resolution of Peripheral Neuropathy (PN) Events
daysIxazomib
Time to Resolution of Peripheral Neuropathy (PN) Events24.0 (7.0 to NA)
SecondaryTime to Improvement of PN Events

PN is defined as the event in the high-level term of peripheral neuropathies NEC according to the MedDRA. A PN event is considered to be improved if the event improves from the maximum grade; that is, all the grades recorded after the maximum grade are less than the maximum grade. Time to improvement is defined as the time from the initial onset date (inclusive) of the maximum grade to the first onset date that the toxicity grade is below the maximum grade with no higher grade thereafter, or the resolution date, whichever occurs first.

Time frame:
Up to 58.4 months
Reported as:
Median · days
Time to Improvement of PN Events
daysIxazomib
Time to Improvement of PN Events8.0 (7.0 to NA)

Adverse events

Collected over Up to 58.4 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ixazomib1/35 (2.9%)11/35 (31.4%)33/35 (94.3%)
Placebo0/4 (0%)0/4 (0%)4/4 (100%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventIxazomibPlacebo
COVID-19Infections and infestations2/350/4
Cardiac failure congestiveCardiac disorders1/350/4
CataractEye disorders1/350/4
Chest discomfortGeneral disorders1/350/4
CholelithiasisHepatobiliary disorders1/350/4
PneumoniaInfections and infestations1/350/4
Femur fractureInjury, poisoning and procedural complications1/350/4
Post procedural haemorrhageInjury, poisoning and procedural complications1/350/4
PeriarthritisMusculoskeletal and connective tissue disorders1/350/4
Rotator cuff syndromeMusculoskeletal and connective tissue disorders1/350/4
Most frequent other events
Showing 10 of 58
Most frequent other events
EventIxazomibPlacebo
ArthralgiaMusculoskeletal and connective tissue disorders5/352/4
PruritusSkin and subcutaneous tissue disorders1/352/4
Upper respiratory tract infectionInfections and infestations14/351/4
DiarrhoeaGastrointestinal disorders12/351/4
VomitingGastrointestinal disorders9/350/4
Breath odourGastrointestinal disorders0/351/4
GastritisGastrointestinal disorders2/351/4
Tongue ulcerationGastrointestinal disorders0/351/4
NasopharyngitisInfections and infestations5/351/4
Weight increasedInvestigations2/351/4

Baseline characteristics

Efficacy Population included all participants who received ixazomib treatment for the duration of their study participation. As prespecified in the statistical analysis plan (SAP), the Efficacy Population contained only one arm i.e., Ixazomib (data for the participants who received placebo before Protocol Amendment 8 was not collected per statistical analysis plan), thus data is presented accordingly.

Age, Continuous
Age, Continuous(years)Ixazomib
Mean65.80 ± 7.551
Sex: Female, Male
Sex: Female, Male(Participants)Ixazomib
Female12
Male21
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Ixazomib
Hispanic or Latino0
Not Hispanic or Latino33
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Ixazomib
American Indian or Alaska Native0
Asian33
Native Hawaiian or Other Pacific Islander0
Black or African American0
White0
More than one race0
Unknown or Not Reported0
07

Study locations

10 sites
  • Beijing Chaoyang Hospital Capital Medical University
    Beijing, Beijing 100020, China
  • Peking University Third Hospital
    Beijing, Beijing 100191, China
  • Peking Union Medical College Hospital
    Beijing, Beijing 100730, China
  • Tongji Hospital Tongji Medical College Huazhong University of Science and Technology
    Wuhan, Hubei 430030, China
  • Jiangsu Province Hospital (the First Affiliated Hospital With Nanjing Medical University)
    Nanjing, Jiangsu 210029, China
  • Shengjing Hospital of China Medical University
    Shenyang, Liaoning 110004, China
  • Renji Hospital Shanghai Jiaotong University School of Medicine
    Shanghai, Shanghai 200001, China
  • Shanghai Chang Zheng Hospital
    Shanghai, Shanghai 200003, China
  • Ruijin Hospital Shanghai Jiaotong University School of Medicine
    Shanghai, Shanghai 200025, China
  • 1st Affiliated Hospital of Zhejiang University
    Hangzhou, Zhejiang 310003, China
08

References and documents

Study documents

  • Study protocol · Aug 26, 2022
  • Statistical analysis plan · Jun 29, 2022

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Sap, Icf, Csr

09

Registry details

Key details

Study ID
NCT03748953
Lead sponsor
Millennium Pharmaceuticals, Inc.
Responsible party
Sponsor
First posted
Nov 21, 2018
Start date
Jan 24, 2019
Primary completion
Dec 6, 2023
Completion
Dec 6, 2023
Results posted
Mar 21, 2025
Last update
Mar 21, 2025

Study contacts

Medical Director
study director · Takeda

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Multiple Myeloma→

Other studies from this sponsor

Millennium Pharmaceuticals, Inc.

Start the discussion